Terms ending in 2029
Every in-force patent on Eth Zurich's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,377,463 | Method for Biomarker and Drug-Target Discovery for Prostate Cancer Diagnosis and Treatment as Well as Biomarker Assays Determined Therewith In force · High confidence | Eth Zurich | In force | High confidence | |
| US 10,151,755 | Method for Biomarker and Drug-Target Discovery for Prostate Cancer Diagnosis and Treatment as Well as Biomarker Assays Determined Therewith In force · High confidence | Eth Zurich | In force | High confidence | |
| US 8,148,344 | Compositions and Methods for Mediating Rnai in Vivo In force · High confidence | Eth Zurich | In force | High confidence | |
| US 8,324,366 | Compositions and Methods for Delivering Rnai Using Lipoproteins In force · High confidence | Eth Zurich | In force | High confidence | |
| US 8,388,945 | Degradable Microcapsules In force · High confidence | Swissgenetics Genossenschaft | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Eth Zurich.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.